The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer
Myung Hee Chang, Jin Seok Ahn, Jeeyun Lee, Kyoung Ha Kim, Yeon Hee Park, Joungho Han, Myung-Ju Ahn, Keunchil Park
20100801
2010 Sept 1
Lung Cancer
The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer
Lung Cancer. 2010 Sept;69(3):323-329, Myung Hee Chang, Jin Seok Ahn, Jeeyun Lee, Kyoung Ha Kim, Yeon Hee Park, Joungho Han, Myung-Ju Ahn, Keunchil Park
BackgroundPemetrexed is one of the standard second-line therapies in advanced non-small cell lung cancer (NSCLC). Currently, there are no standard cytotoxic treatments beyond second-line therapy. We evaluated the efficacy and safety of pemetrexed as a salvage regimen in heavily pretreated NSCLC patients. We also analyzed thymidylate synthase (TS) expression in tumor tissues to determine whether TS expression is correlated with the clinical efficacy of pemetrexed.MethodsOne hundred and ten NSCLC patients...
Editors' Choice
Long-Term Posttransplant Bortezomib Boosts Outcome in Myeloma With del(17p13)
